Skip to Content

Posts tagged with "Alzheimer’s Disease"

  • Alzheimer's Disease

    Bill Gates and His Moonshot

    The rocket’s supposed to be moving, and it probably is, but everyone knows that you can’t see that with the naked eye. Not at first. The announcer said “Lift-off” – well, that probably happened sometime during the lunch hour, it’s easy to miss – and the first thing you look for is the exhaust starting… Read More
  • Alzheimer's Disease

    Just How Worthless Are the Standard Alzheimer’s Models?

    As mentioned yesterday, Alzheimer’s therapies have, for the most part, been a cliff over which people push bales of money. There are plenty of good reasons for this: we don’t really know what the cause of Alzheimer’s is, when you get down to it, and we’re the only animal that we know of that gets… Read More
  • Alzheimer's Disease

    Does Axovant Have Any Hope in Alzheimer’s?

    Hey, remember Axovant? That’s the company that acquired a shelved Alzheimer’s candidate from GSK (intepirdine) and promptly went public in June of 2015 at what seemed a ridiculous valuation ($15/share, raising $315 million). People certainly made money on it, but jeez, the whole business really had a nasty look to it. The company’… Read More
  • Alzheimer's Disease

    TauRx Reports on Their Alzheimer’s Drug. Unfortunately.

    It’s been a while since we heard from TauRx, the company that’s been developing an unusual Alzheimer’s therapy targeting tau protein instead of amyloid. They released interesting Phase II data some time ago, but they’ve been improving their formulation and going into a larger, longer Phase III, which is what anyone working… Read More
  • Alzheimer's Disease

    Muscarinic Agonists Come Back Around

    Allergan, now that they’re not going to be Pfizer, has wasted no time signing a big deal with Heptares for Alzheimer’s. Heptares, as the receptor-centric people in the readership will know well, has been working on GPCR structure for some years now, and applying this knowledge to their own drug discovery efforts. They have what… Read More
  • Alzheimer's Disease

    Is Lilly’s Big Alzheimer’s Trial in Trouble?

    Eli Lilly has been testing their solanezumab antibody against Alzheimer’s for some years now. The first rounds of clinical trials were. . .inconclusive at best. Perhaps there was a bit of an effect in the mildest-affected patient cohort, perhaps not. The company went for it, though, starting a second Phase III in a more carefully selected p… Read More
  • Alzheimer's Disease

    Microbial Alzheimer’s: The Arguing Continues

    The Journal of Alzheimer’s Disease has published an editorial, signed by thirty-one researchers from institutions across several continents, calling on a re-evaluation of the disease’s origins: We are researchers and clinicians working on Alzheimer’s disease (AD) or related topics, and we write to express our concern that one particu… Read More
  • Alzheimer's Disease

    Unpleasant Alzheimer’s News

    Here are a couple of new developments in Alzheimer’s and dementia – nothing encouraging, unfortunately. A new paper in JAMA Internal Medicine, from a team that’s looked at multiyear patient records, suggests that there’s a dose-response relationship between use of strong anticholinergic drugs and later development of dementi… Read More
  • Alzheimer's Disease

    A Dietary Cause for a Neurodegenerative Disease

    This is an interesting paper in itself, and its potential implications are even more so. The authors, from the Institute for Ethnomedicine and the University of Miami, have been studying a neurodegenerative condition found among Chamorro villagers on the island of Guam. The disease (Guamanian amyotrophic lateral sclerosis/parkinsonism dementia comp… Read More
  • Alzheimer's Disease

    A Fungal Origin For Alzheimer’s?

    Here’s a potentially interesting paper that’s recently appeared, saying that numerous brain regions in Alzheimer’s patients appear to show signs of fungal infection, as opposed to control samples. The authors claim detection through antibodies, and to have isolated fungal DNA as well, identifying several species. The authors (from… Read More
...234...